ClinicalTrials.gg
RecruitingNCT07095062CONNETTOMAUpdated Nov 5, 2026

Electroencephalogram in Patients With Friedreich's Ataxia for the Study of the Structural and Functional Connectome.

An interventional study of HD-EEG recordings, combined with cognitive and motor assessment in Friedreich's Ataxia and Motor Disorders, sponsored by IRCCS Eugenio Medea. Recruiting at 1 site in Italy. Open to participants aged 8 Years to 60 Years. Per ClinicalTrials.gov, last updated 2026-11-05.

Sponsored by IRCCS Eugenio Medea · Not applicable, Interventional, and Basic science

How we know

From the registry’s dates

  • Started Jul 2025; still recruiting 1 year 4 months later.
Updated Nov 5, 2026Primary completion movedStudy completion movedGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
30
Allocation
Not applicable
Ages
8 Years to 60 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-21

Among 22 studies in Friedreich Ataxia with a site in Italy — 5 open to participants now, 8 under way, 2 of them phase 3. Friedreich Ataxia · Italy.

Planned enrollment
10th of 17
30 · median 36
Started
2025
with 4 others
No phase
3 of 22
1 open now
Registered
21st of 22
by date
Lead sponsor
3 of 22
IRCCS Eugenio Medea

Among the 22 studies in Friedreich Ataxia with a site in Italy, this one is the 10th largest by planned enrollment of the 17 interventional ones that give a count, is one of 5 that started in 2025, is one of 3 with no phase, and was the 21st registered.

Friedreich Ataxia

111 studies on the registry are indexed under Friedreich Ataxia; 28 are open to participants now.

Browse Friedreich Ataxia studies →

Open to participants now

5 of the 22 studies in Friedreich Ataxia with a site in Italy are open now. Recruiting first, the newest first:

All 5 open studies →

A study can be open while its sites in Italy have not opened yet or have stopped. Only those recruiting at a site in Italy →

Who these studies take

Of the 18 Friedreich Ataxia studies recruiting now, 9 (50%) set no upper age limit and 9 (50%) stop at 75 or younger; 15 take children under 18; 3 take healthy volunteers.

This study: 8 Years to 60 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 22 studies in Friedreich Ataxia with a site in Italy, or all of them as a file.
02

Study summary

Prospective, exploratory, multicenter pilot study investigating the structural and functional connectome in patients with Friedreich's Ataxia (FRDA) using high-density electroencephalogram (HD-EEG). The aim is to identify neurophysiological biomarkers and analyze the relationship between cortical connectivity, cognitive functioning, and clinical severity, particularly in response to rehabilitation treatment.

Read the detailed description

Friedreich's Ataxia (FRDA) is a progressive neurodegenerative disease caused by mutations in the FXN gene, resulting in a reduction in the mitochondrial protein frataxin and a dysfunction in iron homeostasis. In addition to motor and sensory impairments, FRDA also results in cognitive and emotional deficits. Pathophysiologically, it is associated with cerebellar degeneration and alterations in cerebello-cortical networks.

The present study proposes a novel HD-EEG-based approach to analyze brain activity at resting-state and during the performance of a motor task (task-based) in subjects with FRDA. Thirty patients with confirmed genetic diagnosis, age between 8 and 60 years, and SARA score \<30 will be recruited. EEG recordings will be performed in resting condition and during an upper limb motor task.

In addition to neurophysiological measures, each participant will undergo a comprehensive neuropsychological evaluation, including memory, attention, language, visuospatial skills, praxis, executive functions, emotional and personality aspects. Connectivity data will be correlated with cognitive profiles and scores on the SARA and mFARS clinical scales.

03

Conditions studied

  • Friedreich's Ataxia
  • Motor Disorders

Keywords

  • Functional Connectivity
  • HD-EEG
  • FRDA
  • Connectome
  • Cognitive Functioning
  • Neurodegenerative Disease
  • Cerebellar Disorders
  • Neurophysiological Biomarkers
  • Friedreich Ataxia
04

Who can participate

Ages eligible
8 Years to 60 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • age between 8 and 60 years;
  • genetic diagnosis of FRDA: presence of guanine-adenine trinucleotide (GAA) expansion in the two alleles of the fratassin gene, GAA1 and GAA2;
  • score on the Scale for the Assessment and Rating of Ataxia (SARA) \< 30;
  • ability to take part in a neuropsychological assessment in Italian.

Exclusion criteria

Exclusion criteria:

  • age different from the range 8-60 years;
  • diagnosis of acquired ataxia or other genetic ataxias;
  • SARA scale score ≥ 30;
  • inability to take part in an Italian-language neuropsychological assessment
05

Study design

Phase
Not applicable
Primary purpose
Basic science
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
30 participants (estimated)

Study arms

  • Experimental
    Patients with Friedreich's ataxia undergoing HD-EEG and neurofunctional rehabilitation.

    This arm includes patients with a confirmed genetic diagnosis of Friedreich's Ataxia (FRDA), aged between 8 and 60 years, with SARA scale scores below 30. Participants undergo high-density electroencephalogram (HD-EEG) recording under resting conditions and during a motor task, as well as a comprehensive neuropsychological and emotional assessment. All follow an intensive rehabilitation program lasting 3-4 weeks. HD-EEG recordings are repeated after treatment and one year later to assess longitudinal changes in functional connectivity and identify potential biomarkers associated with clinical progression.

    Device: HD-EEG recordings, combined with cognitive and motor assessment

Interventions

  • DeviceHD-EEG recordings, combined with cognitive and motor assessment

    Participants will undergo high-density EEG (HD-EEG) recordings under two conditions: at rest and while performing an upper limb motor task. The data obtained will be used to reconstruct source cortical activity and derive patterns of functional connectivity, using advanced neurophysiological analysis techniques, including the Avalanche Transition Matrix (ATM). In addition, patients will complete a neuropsychological assessment and participate in an intensive multidisciplinary rehabilitation program lasting 3 to 4 weeks, depending on age. The intervention aims to assess changes in the functional organization of the brain before and after treatment, as well as one year later, in order to explore potential biomarkers of disease progression.

06

What researchers measure

Primary outcomes

  1. Connectivity profile derived from HD-EEG in subjects with FRDA.

    Characterization of alterations in the connectome derived from the HD-EEG of subjects with FRDA compared with matched controls;

    Time frame: From enrollment to the end of treatment at 3 to 4 weeks and after 1 year of follow-up

  2. Functional activity derived from HD-EEG in subjects with FRDA.

    Evaluation of functional connectivity as a biomarker in the evolution of FRDA

    Time frame: From enrollment to the end of treatment at 3 to 4 weeks and after 1 year of follow-up

Secondary outcomes

  1. Correlation between functional connectivity/activity and quantitative parameters derived from neuropsychological scales. Correlation between functional connectivity/activity and quantitative parameters derived from motor scales (SARA and mFARS).

    1. acquisition of new knowledge about the neuronal basis of impaired neurocognitive functioning in FRDA; 2. evaluation of possible correlations with disease severity scales pre- and post-rehabilitation treatment.

    Time frame: From enrollment to the end of treatment at 3 to 4 weeks and after 1 year of follow-up

07

Study locations

1 of 1 sites recruiting
08

References and documents

Individual participant data

Plan to share: Yes — Anonymized individual participant data will be shared with other researchers upon reasonable request

Supporting information: Study protocol, Statistical analysis plan, Informed consent form, Clinical study report, Analytic code

Time frame: Start date: January 2028 End date: January 2038

Access criteria: Any researchers accredited by non-profit clinical and research center

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it moved

Started Jul 2025 (actual). Primary completion is estimated for Dec 2027, 29 months after the start.

Since we started tracking on Sep 25, 2026, the dates moved once, on Nov 5, 2026: primary completion Dec 2026 → Dec 2027 and completion Dec 2026 → Dec 2027.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Jul 2, 2025
First posted
Jul 31, 2025
StartActual
Jul 7, 2025
Primary completionEst.
Dec 31, 2027was Dec 2026
CompletionEst.
Dec 31, 2027was Dec 2026
Last update
Nov 5, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Primary completion
Dec 31, 2026→Dec 31, 2027
Nov 5, 2026
Study completion
Dec 31, 2026→Dec 31, 2027
Nov 5, 2026
Show all 1 update
  1. Nov 5, 2026
    Primary completion Dec 31, 2026→Dec 31, 2027
    Study completion Dec 31, 2026→Dec 31, 2027
    + 1 other change: verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07095062
Responsible party
Sponsor
First posted
Jul 31, 2025
Start date
Jul 7, 2025
Primary completion
Dec 31, 2027 (estimated)
Completion
Dec 31, 2027 (estimated)
Last update
Nov 5, 2026

Study contacts

Gabriella Paparella, Medical Degree
Contact
gabriella.paparella@lanostrafamiglia.it
+39 04389062
Gabriella Paparella, Medical Doctor
principal investigator · IRCCS E. Medea / Associazione la Nostra Famiglia

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion